CN109563083A - 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 - Google Patents
喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 Download PDFInfo
- Publication number
- CN109563083A CN109563083A CN201780048635.0A CN201780048635A CN109563083A CN 109563083 A CN109563083 A CN 109563083A CN 201780048635 A CN201780048635 A CN 201780048635A CN 109563083 A CN109563083 A CN 109563083A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- crystal form
- maleate
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供了式(I)所示的喹唑啉衍生物类酪氨酸激酶抑制剂的马来酸盐及其晶型和制备方法，含有该马来酸盐及其晶型的药物组合物，以及该马来酸盐及其晶型在制备用于治疗和/或预防过度增生疾病和慢性阻塞性肺病的药物中的应用。
Description
PCT国内申请，说明书已公开。
Claims (11)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016106634705 | 2016-08-12 | ||
| CN201610663470 | 2016-08-12 | ||
| PCT/CN2017/097078 WO2018028673A1 (zh) | 2016-08-12 | 2017-08-11 | 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109563083A true CN109563083A (zh) | 2019-04-02 |
| CN109563083B CN109563083B (zh) | 2020-11-10 |
Family
ID=61162864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780048635.0A Active CN109563083B (zh) | 2016-08-12 | 2017-08-11 | 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US11111234B2 (zh) |
| CN (1) | CN109563083B (zh) |
| WO (1) | WO2018028673A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112010839B (zh) * | 2019-05-31 | 2022-06-17 | 轩竹生物科技股份有限公司 | 靶向丝/苏氨酸激酶抑制剂的晶型 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011098607A1 (de) * | 2010-02-15 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Salze und hydrate des 4 -[(3-chlor-4-fluor-phenyl)amino]-6-(cis-4-{n-[(morph-1-olin-4-yl)carbonyl]-n-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-chinazolins, deren verwendung als arzneimittel und deren herstellung |
| WO2012159457A1 (zh) * | 2011-05-26 | 2012-11-29 | 山东亨利医药科技有限责任公司 | 喹唑啉衍生物类酪氨酸激酶抑制剂及其制备方法与应用 |
| CN103965175A (zh) * | 2013-02-05 | 2014-08-06 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
-
2017
- 2017-08-11 CN CN201780048635.0A patent/CN109563083B/zh active Active
- 2017-08-11 US US16/325,051 patent/US11111234B2/en active Active
- 2017-08-11 WO PCT/CN2017/097078 patent/WO2018028673A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011098607A1 (de) * | 2010-02-15 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Salze und hydrate des 4 -[(3-chlor-4-fluor-phenyl)amino]-6-(cis-4-{n-[(morph-1-olin-4-yl)carbonyl]-n-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-chinazolins, deren verwendung als arzneimittel und deren herstellung |
| WO2012159457A1 (zh) * | 2011-05-26 | 2012-11-29 | 山东亨利医药科技有限责任公司 | 喹唑啉衍生物类酪氨酸激酶抑制剂及其制备方法与应用 |
| CN103965175A (zh) * | 2013-02-05 | 2014-08-06 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用 |
Non-Patent Citations (1)
| Title |
|---|
| 刘燊: "《EGFR酪氨酸激酶抑制剂的设计、合成及生物活性筛选和类药性化合物库的构建》", 《中国博士学位论文全文数据库（电子期刊）》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210053944A1 (en) | 2021-02-25 |
| CN109563083B (zh) | 2020-11-10 |
| WO2018028673A1 (zh) | 2018-02-15 |
| US11111234B2 (en) | 2021-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1956966B (zh) | 喹唑啉衍生物及其治疗用途 | |
| CN109384799B (zh) | 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物 | |
| CN115803330A (zh) | 4-氨基-5-(6-(4-甲基哌嗪-1-基)-1H-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7H)-酮的盐和晶型 | |
| CA2719523C (en) | Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof | |
| JP2020521003A (ja) | 重水素化ａｚｄ９２９１の結晶形、製造方法および使用 | |
| CA3089243C (en) | Crystal form targeting cdk4/6 kinase inhibitor | |
| EP3613746B1 (en) | Compound of eoc315 mod.i crystal form and preparation method therefor | |
| CN114404415A (zh) | 吲唑类化合物用于治疗银屑病的用途 | |
| CN109563083A (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 | |
| CN103896863B (zh) | 抗癌化合物zd1839的晶型及其制备方法 | |
| JP7036798B2 (ja) | キナゾリン誘導体の塩の結晶 | |
| WO2021147996A1 (zh) | 一种芳胺基嘌呤衍生物的盐及其制备方法和应用 | |
| CN105646461B (zh) | S构型4-(取代苯胺基)喹唑啉衍生物及其制备方法和用途 | |
| JP2022517396A (ja) | Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法 | |
| CN107721985A (zh) | 喹唑啉类酪氨酸激酶抑制剂的晶型 | |
| EP4092021A1 (en) | Crystal form of polycyclic anaplastic lymphoma kinase inhibitor | |
| CN106188017B (zh) | R构型4-(取代苯胺基)喹唑啉衍生物及其制备方法和用途 | |
| CN107721987A (zh) | 喹唑啉类酪氨酸激酶抑制剂的晶型 | |
| CN107721986A (zh) | 喹唑啉类酪氨酸激酶抑制剂的晶型 | |
| CN103664738B (zh) | 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物 | |
| AU2013231084B2 (en) | The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | |
| CN114051498A (zh) | Pi3k抑制剂的结晶多晶型物及其制备方法 | |
| CN110437163A (zh) | 作为酪氨酸激酶抑制剂的嘧啶类化合物 | |
| JP2003514803A (ja) | 結直腸ガンの発達を防止するための４−（４’−ヒドロキシフェニル）アミノ−６，７−ジメトキシキナゾリン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1262858 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |